Dermavant engineers $160M deal to pay off GlaxoSmithKline milestones, gear up to launch psoriasis cream
Dermavant has never been shy about its dreams to transform dermatology with their topical cream. And the Roivant subsidiary has now found investors just as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
